WeVote
Log In

Bill

Bill

HB 417

Criminal Law - Schedule III Controlled Dangerous Substances - Medetomidine and Xylazine

2026 Regular Session Introduced by Tiffany Alston and 19 co-sponsors

Maryland bill HB 417 regulates xylazine and medetomidine to protect consumers from these veterinary sedatives increasingly contaminating illicit drug supplies.

Motion Special Order until Next Session (Senator Love) Adopted
0
WeVote Research Nonpartisan
Bill Summary · HB 417

Legislative bill overview

HB 417 aims to protect consumers from xylazine and medetomidine, two sedative drugs increasingly appearing in the illicit drug supply. The bill likely establishes regulations, warning requirements, or restrictions on these substances to address public health concerns related to their presence in street drugs, particularly in counterfeit pills and powder drugs.

Why is this important

Xylazine ("tranq") and medetomidine are veterinary sedatives that have emerged as serious adulterants in illicit drugs, complicating overdose response and creating withdrawal syndromes unresponsive to naloxone. Maryland, like many states, has seen rising overdose deaths and emergency room visits involving these substances, making regulatory action a public health priority.

Potential points of contention

  • Defining "consumer protection": Unclear whether the bill criminalizes possession/distribution, requires labeling on legal sales, or focuses on warning campaigns—each approach has different enforcement implications
  • Scope and effectiveness: Veterinary drugs are already federally controlled; state-level restrictions may have limited impact on illicit supply while potentially affecting legitimate veterinary use
  • Treatment and harm reduction: Stakeholders may debate whether resources should prioritize prosecution versus addiction treatment, wound care, and naloxone distribution for users already exposed

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.